Lupin (Large Cap - Potential Multibagger) Share Target 2026, 2027 To 2035
|
Lupin Limited |
|||
|
Price: ₹2,273.10 (-0.88%) | ||
| 52 Week Low: ₹1,836.80 52 Week High: ₹2,494.00 |
|||
| Market Capital: 1,07,043.91 Crore (Large-cap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Share Price HistoryLUPIN FinancialsTomorrow TargetYearly TargetsDividend HistoryBonus HistorySplit History
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Lupin Share Price Target For 2026
- 1.1.1: Lupin Share Price Target Table For 2026
- 1.1.2: Short-Term Technical Outlook
- 1.2: Lupin Share Price Target For 2027
- 1.2.1: Lupin Share Price Target Table For 2027
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Lupin Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
- 3: Lupin Brief Company Overview
- 4: Lupin Financial Performance
- 4.0.1: Is Lupin A Good Buy For Long Term?
Lupin, a Large Cap company in the Drug Manufacturers - Specialty & Generic Industry has delivered 176.2% returns in 3-year showing 12.6% quarterly revenue growth with 12.2% profit margin, making it a potential Multibagger.
To predict the Lupin's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Lupin Share Price Target For 2026
The line chart displays the monthly closing prices of Lupin with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Lupin shares in 2026, see the table below.
Lupin Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 2388.74 (+5.08%) | Trend: Supertrend Resistance |
| 2026 Target 2 | 2297.07 (+1.05%) | Volatility: BB Upper |
| 2026 Target 1 | 2296.58 (+1.03%) | Trend: SMA50 |
| Current Price | 2273.10 | Lupin's share price as of 15 Jun 2026 |
| Stop Loss 1 | 2269.64 (-0.16%) | Trend: EMA9 |
| Stop Loss 2 | 2242.95 (-1.33%) | 38.20% Weekly Fib Retrace |
| Stop Loss 3 | 2241.52 (-1.39%) | Volatility: BB Lower |
Short-Term Technical Outlook
Current Technical Position: Lupin is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 50-day moving average at ₹2296.58 serves as the nearest technical reference point.
Historical Returns: 3-month: -0.76% | 6-month: +8.63% | 1-year: +14.69%
Lupin Share Price Target For 2027
The line chart displays the monthly closing prices of Lupin with a black line. The green line shows three potential target prices for 2027, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Lupin shares in 2027, see the table below.
Lupin Share Price Target Table For 2027
| Level | Value | Analysis |
|---|---|---|
| 2027 Target 3 | 2388.74 (+5.08%) | Trend: Supertrend Resistance |
| 2027 Target 2 | 2297.07 (+1.05%) | Volatility: BB Upper |
| 2027 Target 1 | 2296.58 (+1.03%) | Trend: SMA50 |
| Current Price | 2273.10 | Lupin's share price as of 15 Jun 2026 |
| Stop Loss 1 | 2269.64 (-0.16%) | Trend: EMA9 |
| Stop Loss 2 | 2242.95 (-1.33%) | 38.20% Weekly Fib Retrace |
| Stop Loss 3 | 2241.52 (-1.39%) | Volatility: BB Lower |
Long-Term Technical Outlook
52-Week Range Analysis: Lupin is currently trading at 66.4% of its 52-week range (₹1836.8 - ₹2494).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +14.69% | 3-year: +176.15% | 5-year: +98.45%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Lupin Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹2,273.10 | ||
| 2026 | ₹2,890.40 | +27.156746293608% | ₹2,933.76 |
| 2027 | ₹4,040.71 | +39.7976058677% | ₹4,101.32 |
| 2028 | ₹5,084.40 | +25.829371570838% | ₹5,160.67 |
| 2029 | ₹7,159.37 | +40.810518448588% | ₹7,266.76 |
| 2030 | ₹9,649.49 | +34.781272653879% | ₹9,794.23 |
| 2031 | ₹12,100.86 | +25.404140529707% | ₹12,282.37 |
| 2032 | ₹15,781.91 | +30.419738762369% | ₹16,018.64 |
| 2033 | ₹20,141.75 | +27.625553561008% | ₹20,443.88 |
| 2034 | ₹23,599.93 | +17.169213201435% | ₹23,953.93 |
| 2035 | ₹28,638.11 | +21.348283660163% | ₹29,067.68 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Lupin Brief Company Overview
Lupin Limited: A Pharmaceutical Giant Established in 1968, Lupin Limited is a renowned pharmaceutical company headquartered in Mumbai, India. Key Products and Services: Branded and generic formulations Biotechnology products Active pharmaceutical ingredients...
(APIs) Biosimilars Over-the-counter products Drug discovery and development Bio clinical research Market Presence: Lupin operates globally through a network of labs, LupiMitra collection centers, and pick-up points. Reputation: Lupin Limited has earned a strong reputation in the pharmaceutical industry for its commitment to: Innovation and research Quality and affordability Patient care Diversity: Lupin's diverse product range caters to various therapeutic areas, including: Cardiovascular Diabetology Asthma Gastrointestinal Anti-infective Respiratory Women's health Anti-tuberculosis Oncology Immunology Metabolic disordersLupin Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 91,962.06 Crore | Market valuation of Lupin's shares. |
| Revenue (TTM) | 21,431.25 Crore | Total revenue generated by Lupin over the past twelve months. |
| Net Income (TTM) | +2,626.48 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 19.56% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 12.25% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+12.6% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+74.09% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
21.89 | Company's total debt divided by total shareholder equity. |
| Total Debt | 3,442.49 Crore | Sum of Lupin's current & long-term financial obligations. |
| Total Cash | 2,912.31 Crore | Total amount of liquid funds available to Lupin. |
| Beta | 0.58 | Beta is less than 1 indicating that the Lupin's price is less volatile than the market. |
Is Lupin A Good Buy For Long Term?
No valid response content found
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
